84 related articles for article (PubMed ID: 20402568)
21. Mesangial proliferative glomerulonephritis with deposits of anti-nicotinic acetylcholine receptor antibody in a patient with myasthenia gravis.
Mitsui T; Okada K; Kuhara T; Hashizume T; Okazaki S; Kawajiri M; Matsumoto T
J Clin Neurosci; 2001 Sep; 8(5):454-6. PubMed ID: 11535018
[TBL] [Abstract][Full Text] [Related]
22. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
Pachner AR
Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
[TBL] [Abstract][Full Text] [Related]
23. Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein.
Kawanami S; Mori S
Fukuoka Igaku Zasshi; 1994 Apr; 85(4):120-7. PubMed ID: 8200609
[TBL] [Abstract][Full Text] [Related]
24. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
25. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
26. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.
Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH
Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867
[TBL] [Abstract][Full Text] [Related]
27. A new mouse model of autoimmune ocular myasthenia gravis.
Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
[TBL] [Abstract][Full Text] [Related]
28. Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains.
Lazaridis K; Evaggelakou P; Bentenidi E; Sideri A; Grapsa E; Tzartos SJ
J Neuroimmunol; 2015 Jan; 278():19-25. PubMed ID: 25595248
[TBL] [Abstract][Full Text] [Related]
29. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
Barkas T; Simpson JA
J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
[TBL] [Abstract][Full Text] [Related]
30. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
[TBL] [Abstract][Full Text] [Related]
31. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis.
Deng C; Goluszko E; Baron S; Wu B; Christadoss P
J Immunol; 1996 Dec; 157(12):5675-82. PubMed ID: 8955221
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.
Melms A; Chrestel S; Schalke BC; Wekerle H; Mauron A; Ballivet M; Barkas T
J Clin Invest; 1989 Mar; 83(3):785-90. PubMed ID: 2466050
[TBL] [Abstract][Full Text] [Related]
33. Comparison of antigenic sources for acetylcholine receptor antibody assays in myasthenia gravis.
McAdams MW; Roses AD
Ann Neurol; 1980 Jul; 8(1):61-6. PubMed ID: 6773466
[TBL] [Abstract][Full Text] [Related]
34. Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients.
Zhang Y; Schluep M; Frutiger S; Hughes GJ; Jeannet M; Steck A; Barkas T
Eur J Immunol; 1990 Dec; 20(12):2577-83. PubMed ID: 2269325
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of myasthenia gravis.
Hughes BW; Moro De Casillas ML; Kaminski HJ
Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
[TBL] [Abstract][Full Text] [Related]
36. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.
Vincent A; Newsom-Davis J
Clin Exp Immunol; 1982 Aug; 49(2):266-72. PubMed ID: 7127905
[TBL] [Abstract][Full Text] [Related]
37. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria.
Gomez CM; Richman DP
J Immunol; 1987 Jul; 139(1):73-6. PubMed ID: 3035025
[TBL] [Abstract][Full Text] [Related]
38. [Autoantibodies in Myasthenia Gravis].
Higuchi O
Brain Nerve; 2018 Apr; 70(4):419-426. PubMed ID: 29632289
[TBL] [Abstract][Full Text] [Related]
39. A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells.
Homma M; Uzawa A; Tanaka H; Kawaguchi N; Kanai T; Nakajima K; Narita M; Hara Y; Maruyama H; Ogawa Y; Himuro K; Kuwabara S
Neurotherapeutics; 2017 Jan; 14(1):191-198. PubMed ID: 27677608
[TBL] [Abstract][Full Text] [Related]
40. Expression of nicotinic acetylcholine receptor subunits in HEp-2 cells for immunodetection of autoantibody specificities in sera from Myasthenia gravis patients.
George S; Noack M; Vanek M; Rentzsch J; Röber N; Conrad K; Roggenbuck D; Küpper JH
Clin Hemorheol Microcirc; 2015; 61(2):385-96. PubMed ID: 26410878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
